Raymond James Downgrades Apellis Pharmaceuticals to Outperform, Lowers Price Target to $52

Benzinga · 05/09/2025 16:37
Raymond James analyst Ryan Deschner downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Strong Buy to Outperform and lowers the price target from $75 to $52.